Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06487351 · ClinicalTrials.gov registry record · NA

Intervention to Reduce Implicit Bias in Pharmacies

A NA study, sponsored by Massachusetts General Hospital.

Not yet
Registry status
NA
Development phase
70
Enrollment target

NCT06487351: Clinical Trial NA study, sponsored by Massachusetts General Hospital.

NCT06487351 is a NA study that has not yet begun recruiting, run by Massachusetts General Hospital. The registered enrollment target is 70 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT06487351, a NA study, has not yet begun recruiting, sponsored by Massachusetts General Hospital.

NOT YET RECRUITING
Registry status
NA
Development phase
70 participants
Enrollment target

Study Summary

This study will follow the ADAPT-ITT model to apply the Prejudice Habit Breaking Intervention (PHBI) to pharmacists who have experience with or are willing to prescribe PrEP. We will first collect qualitative data through focus group discussions guided by the Health Equity Implementation Framework (HEIF) on determinants related to the intervention itself, pharmacists, and the community pharmacy context that may impact implementation of the PHBI. Then, we will use this information to adapt the PHBI in an iterative process involving topic experts, pharmacists, and PrEP users. We will then determine the feasibility, acceptability, and preliminary impact of the adapted PHBI to reduce implicit racial bias.

Primary Outcome

Acceptability will be assessed in all participants by the Acceptability of Intervention Measure (AIM)

Interventions

  • BEHAVIORAL The adapted PHBI
  • BEHAVIORAL The NIH Implicit Bias course

Trial Details

FieldValue
Enrollment Target 70 participants
Start Date 2027-07
Est. Completion 2029-07
Phase NA
Massachusetts General Hospital

2,032 total trials

What is known before NCT06487351 opens enrollment

NCT06487351 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower).

The record links to 0 conditions, and to 2 interventions - of which The adapted PHBI is the first listed.

NCT06487351 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT06487351 about?

NCT06487351 is a clinical study titled "Intervention to Reduce Implicit Bias in Pharmacies". This study will follow the ADAPT-ITT model to apply the Prejudice Habit Breaking Intervention (PHBI) to pharmacists who have experience with or are willing to prescribe PrEP. We will first collect qualitative data through focus group discussions guided by the Health Equity Implementation Framework (...

What is the current status of trial NCT06487351?

This trial is currently not yet recruiting. It is a NA study. The enrollment target is 70 participants. The study started on 2027-07. Estimated completion is 2029-07.

What interventions are being tested in trial NCT06487351?

The interventions under investigation include: The adapted PHBI (BEHAVIORAL), The NIH Implicit Bias course (BEHAVIORAL).

Who is sponsoring clinical trial NCT06487351?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT06487351's enrollment target sits among peer trials

70 1103rd of 2000 higher than 868 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00969111 · 70 participants · NA

    Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy

  • NCT01712620 · 70 participants · Phase 2

    Spironolactone for Pulmonary Arterial Hypertension

  • NCT02143830 · 70 participants · Phase 2

    HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy

  • NCT02601339 · 70 participants

    NIRS Monitoring in Premature Infants

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT06487351, the US trial registry maintained by the National Library of Medicine. NCT06487351 (small enrollment · none site footprint · not yet recruiting) retrieved and formatted by PlainTrial, see methodology.